Product Description
Mechanisms of Action: SDC Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biotest
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple Myeloma|Triple Negative Breast Cancer|Transitional Cell Carcinoma|Bladder Cancer
Phase 1: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01638936 | P2 |
Completed |
Multiple Myeloma |
2018-10-30 |
2019-08-10 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
| INTRAIN-BB (INdaTuximab RAvtansin effect IN Breast and Bladder cancer) | P2 |
Completed |
Bladder Cancer|Transitional Cell Carcinoma|Triple Negative Breast Cancer |
2017-08-04 |
2022-03-13 |
Treatments |
|
| NCT01001442 | P2 |
Completed |
Multiple Myeloma |
2014-07-01 |
2019-03-19 |
Treatments |
|
| NCT00723359 | P1 |
Completed |
Multiple Myeloma |
2012-04-01 |
2019-03-18 |
Treatments |